《新股消息》微創機器人(02252.HK)料產品獲批後迅速可推進商業化應用
微創機器人(02252.HK)執行董事兼總裁何超指,手術機器人於國外是重要醫療發展方向,目前在各個領域都廣泛應用,而國內市場滲透嚴重不足且發展空間龐大,預期今年底至明年集團將有數款產品獲批可上市,取得註冊批準後將加快推進大規模商用及臨牀應用。
首席商務官兼資深副總裁劉雨補充,公司着重醫生培訓,目前已設立約10家培訓中心,爲醫院及外科醫生提供全面支援,預期有助將手術機器人推廣至國內地級市醫院,達到手術普及化,降低普羅大衆獲得複雜治療的門檻。
微創機器人首日掛牌,董事會主席兼非執行董事孫洪斌表示,對股價表現相當滿意,又指母公司微創醫療(00853.HK)在歐美骨科領域佈局完善,預期未來可產生協同效應。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.